You are here: Urology Textbook > Drugs in Urology > Alpha-blocker > Terazosin
Alpha-Blocker (2/5): Terazosin
- Alpha-blocker (1/6): General pharmacology
- Alpha-blocker (2/6): Terazosin
- Alpha-blocker (3/6): Doxazosin
- Alpha-blocker (4/6): Tamsulosin
- Alpha-blocker (5/6): Alfuzosin
- Alpha-blocker (6/6): Silodosin
Review Literatur: (Chapple, 2004).
General Pharmacology of Terazosin
Please see section general pharmacology of alpha-blocker.
Mechanism of Action of Terazosin
Terazosin is a non-selective alpha1-blocker with a long elimination half-life.
Indications for Terazosin
- Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia
- Treatment of arterial hypertension
Pharmacokinetics of Terazosin
- Bioavailability 90%
- Elimination half-life 10–18 h
Terazosin: Mechanism of Action
Postsynaptic alpha1-blockade leads to:
- Arterial and venous vasodilation, hypotension
- Smooth muscle relaxation of the prostate, bladder neck and the urethra. Alpha-blocker improve the dynamic component of subvesical obstruction due to benign prostatic hyperplasia (BPH).
- Positive effect on the lipid metabolism by lowering cholesterol and triglycerides
Side Effects of Terazosin
- Hypotension, orthostatic syncope, reflex tachycardia
- Stuffy nose
- Retrograde ejaculation
- Tachyphylaxis in the treatment of hypertension due to volume retention and peripheral edema.
- Dizziness, weakness
- Overall rate of side effects is between 10–30%
Contraindications of Terazosin
Conservative treatment of BPH is not indicated, if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections and bladder stones.
Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.
Terazosin should be paused perioperatively for cataract surgery to prevent an intraoperative floppy iris syndrome.
Dosage of Terazosin
2–10~mg 0-0-1, titrate dosage after effect and side-effects, first week 1 mg, second week 2 mg, third week 5 mg, if necessary and possible fourth week 10 mg.
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
- Chapple 2004 CHAPPLE, C. R.:
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary
tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44
Deutsche Version: Terazosin